France In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

France In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

France In-Vitro Diagnostic Market is expected to witness a CAGR of 7.5% over the forecast period.

The emergence of the COVID-19 pandemic had a significant impact on France in-vitro diagnostic market owing to the factors such as delayed diagnostic tests and the scarcity of laboratory reagents to perform tests. For instance, as per the article published in March 2022 in PubMed, based on data from the French administrative healthcare database (SNDS) on the entire French population (67 million people), screening, diagnostic and therapeutic activity was monitored and compared the post-pandemic situation every month, and a significant decline in all activities was observed during the first lockdown in France. However, COVID-19 diagnostic tests were widely carried out during the pandemic, which was one of the factors that significantly affected the market growth. The market is anticipated to witness growth in the coming years due to the rise in chronic diseases and the increase in demand for early diagnosis and point of care.

Certain factors that are also propelling the market growth are the rising incidence of chronic diseases, increasing awareness and acceptance of personalized medicine and companion diagnostics, and the increasing use of point-of-care (POC) diagnostics. The rising burden of chronic diseases such as infectious diseases, cardiovascular diseases, cancers, and others is the main factor driving the demand for the in-vitro diagnostics market over the forecast period. For instance, according to the IDF Atlas 10th edition published in 2021, about 3,942.9 thousand people were living with diabetes in France in 2021. In addition, as per the same source, this number is projected to reach 4,184.9 thousand by 2030 and 4,225.7 thousand by 2045. Furthermore, the increasing use of point-of-care diagnostics in the country as well as initiatives taken to increase awareness and testing for chronic diseases, is also contributing to the growth of the market. For instance, In March 2022, France launched a new colon-cancer testing system for people aged 50-74 years.

Thus, due to the rise in chronic diseases, and the increase in invitro diagnostics product launches, the France in-vitro diagnostics market is anticipated to witness growth in the market over the forecast period. However, the stringent regulations related to diagnostic equipment and devices are impeding the market growth over the forecast period.

The infectious diseases segment is expected to witness significant growth in the in-vitro diagnostics market over the forecast period owing to factors such as the rising prevalence of infectious diseases and rising awareness among the population, and growing demand for point-of-care diagnostics.

The increasing prevalence of infectious diseases such as HIV/AIDS, tuberculosis, hepatitis B, hepatitis C, and others are the key factor driving the demand for the in-vitro diagnostics market in the country. For instance, as per the data published by the WHO, as of November 2022, 37,600,262 confirmed cases of COVID-19 were reported in France. Thus, the high number of coronavirus infections among the population increases the demand for early diagnosis and effective treatment options, thereby propelling the market growth. Moreover, growing awareness regarding early diagnosis and treatment and increasing company focus on developing effective diagnostic products for detecting various infectious diseases are expected to boost market growth over the forecast period. For instance, In March 2021, BioMérieux received the CE marking of its innovative and fully automated test VIDAS TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection.

Thus, due to the rise in infectious disease, and the increase in invitro diagnostics product launches, the infectious disease segment is anticipated to witness growth in the market over the forecast period.

The molecular diagnostics segment is expected to witness significant growth in the France in-vitro diagnostics market over the forecast period owing to factors such as the rising prevalence of chronic and, rising awareness among the population, and growing demand for molecular diagnostics.

The increasing prevalence of chronic diseases, such as cancer, cardiovascular disease, arthritis, and diabetes, is the key factor driving the demand for the molecular diagnostics market in the country. For instance, as per the estimations from IARC, 579,388 cancer cases are anticipated to be diagnosed in France in 2040. As the number of cancer cases increases, the molecular diagnostics tests utilization increases, thereby boosting the market growth.

Product launches, partnerships, and collaboration to increase molecular diagnostics product availability in France are anticipated to drive market growth. For instance, since January 1, 2022, the “HIV Test” operation has enabled all patients who wish to do so to carry out a free HIV test, without prescription or appointment, in any medical biology laboratory in France. Furthermore, in February 2021, the French startup Omini, specializing in the development of portable blood tests, raised EUR 1.7 million in seed from the deep tech investor Entrepreneur First, 6 French networks of businesses (BADGE, AMBA, Angel Santé, INSEAD BA, WeLikeAngels, PSBA) as well as strategic business and the BPI.

Thus, due to the rise in chronic diseases, and the increase in molecular diagnostic product launches, the molecular diagnostics segment is anticipated to witness growth in the market over the forecast period.

France is a developed region with a well-structured healthcare system. As a result, many players in the in-vitro diagnostics market are present in the country. Thus, the in-vitro diagnostic market in France is fairly fragmented, with the presence of local players competing in the market. Some of the players in the market include Abbott Laboratories, F. Hoffmann-La Roche AG, QIAGEN N.V., Siemens Healthineers AG, Thermo Fischer Scientific Inc., BioMerieux and Becton, Dickinson and Company.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support